Ascletis Pharma Inc. expects to record (i) a total revenue ranging from RMB 46.0 million to RMB 47.0million for the six months ended June 30, 2023, representing an increase of approximately 20.4% to 23.0% from approximately RMB 38.2 million for the six months ended June 30, 2022; and (ii) a net loss attributable to the owners of the Company ranging from RMB 14.0 million to RMB 22.0 million for the six months ended June 30, 2023, representing a decrease of approximately 84.1% to 75.0% as compared to that for the six months ended June 30, 2022.